Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Glioblastoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 129 for your search:
Start Over
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 22 and over
Trial IDs: EF-19, NCI-2013-00553, NCT01756729
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Temozolomide and Hypofractionated Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BRN0012, NCI-2011-00043, SU-04202010-5726, NCT01120639
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-122, NCI-2011-01164, NCT01260506
Trebananib with or without Bevacizumab in Treating Patients with Recurrent Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-185, NCI-2013-00273, NCT01290263
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, NCT01325207
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BTTC09-01, NCI-2011-03056, NCT01434602
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: DLM-10-001, NCI-2014-00140, NCT01478178
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: IRB# 55264, NCI-2012-01118, HCI55264, NCT01580969
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
Bevacizumab with or without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients with Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1174, NCI-2012-01989, CDR0000737109, NCCTG-N1174, NCT01648348
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX108-08, NCI-2013-01176, NCT01790503
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTRC# 12-02, NCI-2014-00900, 1149367, 1-874640-1, 193831, 20141749, HSC20140450X, NCI-2014-00412, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120E2102, NCI-2013-02397, 2013-003129-27, NCT01934361
Carboxyamidotriazole Orotate with or without Bevacizumab in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00044274, NCI-2014-00031, NCT01954030
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, NCT01977677
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Start Over